Repositioning Candidate Details

Candidate ID: R1086
Source ID: DB06712
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Nilvadipine
Synonyms: Nilvadipine
Molecular Formula: C19H19N3O6
SMILES: COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
Structure:
DrugBank Description: Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
CAS Number: 75530-68-6
Molecular Weight: 385.3707
DrugBank Indication: For the management of vasospastic angina, chronic stable angina and hypertension.
DrugBank Pharmacology: Nilvadipine is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. Nilvadipine is used to treat Prinzmetal's angina, hypertension, and other vascular disorders such as Raynaud's phenomenon. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.
DrugBank MoA: Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Targets: Voltage-dependent L-type calcium channel subunit alpha-1C inhibitor; Voltage-dependent calcium channel subunit alpha-2/delta-1 inhibitor; Voltage-dependent L-type calcium channel subunit beta-2 inhibitor; Voltage-dependent L-type calcium channel subunit alpha-1D inhibitor; Voltage-dependent L-type calcium channel subunit alpha-1S inhibitor; Voltage-dependent calcium channel subunit alpha-2/delta-3 inhibitor
Inclusion Criteria: Indication associated